Wavelength Pharmaceuticals Overview
Wavelength Pharmaceuticals develops and manufactures active pharmaceutical ingredients and select finished dosage forms. The company focuses on differentiated products that require sophisticated manufacturing processes. Its solution provides customers with comprehensive technical support and in-depth regulatory support across the entire product lifecycle, from project inception to commercial production. Wavelength Pharmaceuticals core strengths include complex chemistry, innovative process development, crystalline forms, and particle design. It tailors customized solutions to meet individual customer requirements, including full spectrum API CDMO services from preclinical grams to multi-ton commercial quantities.
Latest News
growth-positive
On Demand Pharmaceuticals and Wavelength Pharmaceuticals Awarded BIRD Foundation Grant
On Demand Pharmaceuticals, Inc. (ODP) and Wavelength Pharmaceuticals are receiving a $1M investment from the US-Israel Binational Industrial Research & Development (BIRD) Foundation to advance on-demand, point-of-care medicine manufacturing. ODP and Wavelength Pharmaceuticals will leverage their manufacturing capabilities to strengthen the supply of essential medicines and their ingredients. The combination of their platforms aims to improve resource utilization and reduce cycle times in producing medicines. The current drug shortages, driven by economic crisis, global supply chain complexities, and pricing policies, pose a threat to public health. ODPs Pharmacy on Demand platform offers a rapid response capability to meet surges in demand and mitigate supply chain risks. The investment will support the development of a reliable supply of medicines.
Investment
growth-positive
Tikun olam-Cannbit continues to expand its footprint in the pharmaceutical arena
Tikun-Olam Cannbit has entered into a partnership with Wavelength, an Israeli company that develops and exports active pharmaceutical ingredients (APIs) for the pharmaceutical industry. The partnership aims to jointly develop, manufacture, and market cannabis-based raw materials for the pharmaceutical industry. Wavelength, a portfolio company of SK Capital Partners, has a leading technology plant that operates in compliance with industry standards. The partnership is expected to target the global pharmaceutical market in light of regulatory changes regarding cannabis exports. This partnership signifies a step forward for Tikun-Olam Cannbit in the medical cannabis industry and the pharmaceutical sector.
Partners
Wavelength Pharmaceuticals Further Strengthens Its Global Supply Chain with Acquisition of Vanamali Organics
Wavelength Pharmaceuticals Expands Supplies of Key Drug Ingredients for Critically Ill COVID-19 Patients
growth-positive
Wavelength Ups API Production for Essential Respiratory Meds
Wavelength Pharmaceuticals has expanded production of APIs for pharmaceuticals used to manage respiratory critical care patients due to the coronavirus pandemic. The company has also launched new API CDMO services that leverage its expertise in complex chemistry, crystalline forms, and particle design for the development and manufacturing of new APIs. The companys CEO, Iftach Seri, stated that their robust supply chain and regulatory track record have enabled them to quickly respond to the urgent need for life-saving care for critically ill COVID-19 patients.
CustomersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 1 |
| Investors | 0 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | www.wavelengthpharma.com |
| Careers | Careers page |
Locations
Ramat Hovav, Israel
Shlomo Shmeltzer Road 94, Petah Tikva, Israel
Ronda del General Mitre, 126, Barcelona, Spain
1700 Route 23, Wayne, NJ 07470, USA
Photos & Videos
2 item(s)
Wavelength Pharmaceuticals Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
Materials & SubstancesBiologicalsTags (10)
pharmaceuticalsapiallergysleep-disordersgastroenterologyalzheimers-diseasesupply-chainrespiratorycancerdermatologyGeographic Markets
GlobalWavelength Pharmaceuticals Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Acquired
Funding stage
1
Total rounds
0
Investors
Non-Equity Funding
GrantEvent
Jul 2022
Undisclosed
BIRD Foundation (Lead)
Public Offering / Exit
MNAEvent
Dec 2021
Undisclosed
MNAEvent
Nov 2017
$110M
Mergers & Acquisitions
MNAEvent
Feb 2021
Undisclosed
MNAEvent
Feb 2021
Undisclosed
Wavelength Pharmaceuticals Lifecycle
All Events
GrantEvent
Jul 2022
Undisclosed
BIRD Foundation (Lead)
MNAEvent
Dec 2021
Undisclosed
MNAEvent
Nov 2017
$110M
MNAEvent
Feb 2021
Undisclosed
MNAEvent
Feb 2021
Undisclosed
Wavelength Pharmaceuticals News
8 articles
growth-positive
On Demand Pharmaceuticals and Wavelength Pharmaceuticals Awarded BIRD Foundation Grant
On Demand Pharmaceuticals, Inc. (ODP) and Wavelength Pharmaceuticals are receiving a $1M investment from the US-Israel Binational Industrial Research & Development (BIRD) Foundation to advance on-demand, point-of-care medicine manufacturing. ODP and Wavelength Pharmaceuticals will leverage their manufacturing capabilities to strengthen the supply of essential medicines and their ingredients. The combination of their platforms aims to improve resource utilization and reduce cycle times in producing medicines. The current drug shortages, driven by economic crisis, global supply chain complexities, and pricing policies, pose a threat to public health. ODPs Pharmacy on Demand platform offers a rapid response capability to meet surges in demand and mitigate supply chain risks. The investment will support the development of a reliable supply of medicines.
Investment
growth-positive
Tikun olam-Cannbit continues to expand its footprint in the pharmaceutical arena
Tikun-Olam Cannbit has entered into a partnership with Wavelength, an Israeli company that develops and exports active pharmaceutical ingredients (APIs) for the pharmaceutical industry. The partnership aims to jointly develop, manufacture, and market cannabis-based raw materials for the pharmaceutical industry. Wavelength, a portfolio company of SK Capital Partners, has a leading technology plant that operates in compliance with industry standards. The partnership is expected to target the global pharmaceutical market in light of regulatory changes regarding cannabis exports. This partnership signifies a step forward for Tikun-Olam Cannbit in the medical cannabis industry and the pharmaceutical sector.
Partners
Wavelength Pharmaceuticals Further Strengthens Its Global Supply Chain with Acquisition of Vanamali Organics
Wavelength Pharmaceuticals Expands Supplies of Key Drug Ingredients for Critically Ill COVID-19 Patients
growth-positive
Wavelength Ups API Production for Essential Respiratory Meds
Wavelength Pharmaceuticals has expanded production of APIs for pharmaceuticals used to manage respiratory critical care patients due to the coronavirus pandemic. The company has also launched new API CDMO services that leverage its expertise in complex chemistry, crystalline forms, and particle design for the development and manufacturing of new APIs. The companys CEO, Iftach Seri, stated that their robust supply chain and regulatory track record have enabled them to quickly respond to the urgent need for life-saving care for critically ill COVID-19 patients.
CustomersExpand
Wavelength Pharmaceuticals Names Iftach Seri as Chief Executive Officer and Tami Cohen as Chief Financial Officer
growth-positive
Perrigo completes sale of Israeli unit Chemagis for $110m
Perrigo Company has completed the sale of its Israel-based API unit Chemagis to SK Capital for $110 million. Perrigo API has been renamed Wavelength Pharmaceuticals. SK Capital has appointed four former Teva executives to its board of directors.
Acquisition
growth-positive
SK Capital buys Perrigo's Israel unit Chemagis for $110m
Pharmaceutical company Perrigo has signed an agreement to sell its API unit Chemagis for $110 million to SK Capital. Perrigo acquired Chemagis in 2005 as part of a $818 million acquisition of Agis. Perrigo reported better than expected second quarter results, with revenue of $1.2 billion and a net loss of $70 million. The companys share price rose 12.7% on the Tel Aviv Stock Exchange. Perrigo is currently searching for a new CEO.
AcquisitionInvestment
Wavelength Pharmaceuticals Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 95 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Wavelength Pharmaceuticals Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | funding rounds, markets, not claimed |
| BI Verification | Natalia Golczar |
| Registrar ID | 515666485 |
| Crunchbase | perrigo-api |
| Phone | +97235773880 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-12-06T00:00:00.000Z |
| Created | 2018-06-18T00:00:00.000Z |
| Status detail | Acquired by SK Capital Partners on Nov, 2017 |